Adavosertib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	12	1	47	—	—	Feb 25, 2008
Malignant Ovarian Neoplasm	Phase2	Phase 2	4	0	7	—	—	Jul 26, 2011
Malignant Cervical Neoplasm	Phase2	Phase 2	2	0	4	—	—	May 31, 2010
Malignant Esophageal Neoplasm	Phase2	Phase 2	2	0	2

Curated evidence

Clinical evidence (5)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
WEE1 Overexpression4
Adavosertib	Acute Lymphoblastic Leukemia

Clinical trials

Trials with this intervention (47)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–47 of 47 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03668340	AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	active not recruiting	Phase 2	49	Dana-Farber Cancer InstituteOTHER	1	Sep 28, 2026	clinicaltrials
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting